- Home
- CATX vs IMMP Comparison
CATX vs IMMP Comparison
Compare CATX & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- IMMP
- Stock Information
- Founded
- CATX 1983
- IMMP 1987
- Country
- CATX United States
- IMMP Australia
- Employees
- CATX N/A
- IMMP N/A
- Industry
- CATX Medical/Dental Instruments
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- IMMP Health Care
- Exchange
- CATX Nasdaq
- IMMP Nasdaq
- Market Cap
- CATX 239.0M
- IMMP 221.2M
- IPO Year
- CATX N/A
- IMMP N/A
- Fundamental
- Price
- CATX $3.97
- IMMP $1.67
- Analyst Decision
- CATX Strong Buy
- IMMP Buy
- Analyst Count
- CATX 11
- IMMP 1
- Target Price
- CATX $12.90
- IMMP $7.00
- AVG Volume (30 Days)
- CATX 1.3M
- IMMP 96.5K
- Earning Date
- CATX 08-11-2025
- IMMP 02-27-2025
- Dividend Yield
- CATX N/A
- IMMP N/A
- EPS Growth
- CATX N/A
- IMMP N/A
- EPS
- CATX N/A
- IMMP N/A
- Revenue
- CATX $1,471,000.00
- IMMP $3,019,249.00
- Revenue This Year
- CATX N/A
- IMMP $50.37
- Revenue Next Year
- CATX N/A
- IMMP N/A
- P/E Ratio
- CATX N/A
- IMMP N/A
- Revenue Growth
- CATX N/A
- IMMP 24.11
- 52 Week Low
- CATX $1.60
- IMMP $1.32
- 52 Week High
- CATX $16.55
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- CATX 61.19
- IMMP 46.46
- Support Level
- CATX $3.33
- IMMP $1.64
- Resistance Level
- CATX $3.69
- IMMP $1.74
- Average True Range (ATR)
- CATX 0.38
- IMMP 0.07
- MACD
- CATX 0.01
- IMMP 0.01
- Stochastic Oscillator
- CATX 64.23
- IMMP 69.57
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.